Related Experiment Videos
Aspartylglucosaminuria among Palestinian Arabs
J Zlotogora1, Z Ben-Neriah, B Y Abu-Libdeh
1Rosa and David Orzen Human Genetic Clinic, Department of Human Genetics, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.
Journal of Inherited Metabolic Disease
|January 14, 1998
Summary
Aspartylglucosaminuria (AGU), a rare metabolic disorder, was diagnosed in Palestinian Arab families. Early biochemical screening via urine chromatography is effective for identifying this condition.
Area of Science:
- Biochemistry
- Genetics
- Lysosomal Storage Disorders
Background:
- Aspartylglucosaminuria (AGU) is a rare autosomal recessive disorder of glycoprotein metabolism.
- It results from a deficiency in the lysosomal enzyme aspartylglucosaminidase (AGA).
- AGU is known to have a high frequency in Finland due to a founder effect.
Observation:
- This study identified AGU in 8 patients from 3 unrelated Palestinian Arab families near Jerusalem.
- This is significant as few non-Finnish cases have been previously reported.
- Clinical diagnosis can be challenging, especially in early stages, with most patients diagnosed after age 5.
Findings:
- Biochemical screening is simplified by the early and significant excretion of aspartylglucosamine in urine.
- Urine chromatography proves to be an easy method for detecting AGU.
- The diagnosis in this Palestinian population highlights a broader geographical distribution than previously understood.
Implications:
- This finding expands the known geographical distribution of Aspartylglucosaminuria.
- Early biochemical screening methods can facilitate timely diagnosis and management.
- Understanding AGU prevalence in diverse populations is crucial for genetic counseling and public health initiatives.